Evidence map›Paper›PMID 34043740›Full record

ArticlePLoS pathogens2021

TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2.

Joseph D Trimarco, Brook E Heaton, Ryan R Chaparian, Kaitlyn N Burke, Raquel A Binder, Gregory C Gray, Clare M Smith, Vineet D Menachery, Nicholas S Heaton

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Joseph D TrimarcoDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0001-5463-7144
Brook E HeatonDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0003-2839-3806
Ryan R ChaparianDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0003-3838-1868
Kaitlyn N BurkeDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0002-4868-4494
Raquel A BinderDivision of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, United States of America.
Gregory C GrayDivision of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0002-4628-5908
Clare M SmithDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0003-2601-0955
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Nicholas S HeatonDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0002-5307-3428
Duke University · USThe University of Texas Medical Branch at Galveston · US

Funding

Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Viral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9M
NCI NIH HHS T32 CA009111NIAID NIH HHS UC6 AI058607
6 · The paper itself

Abstract

Antiviral therapeutics are a front-line defense against virally induced diseases. Because viruses frequently mutate to escape direct inhibition of viral proteins, there is interest in targeting the host proteins that the virus must co-opt to complete its replication cycle. However, a detailed understanding of the interactions between the virus and the host cell is necessary in order to facilitate development of host-directed therapeutics. As a first step, we performed a genome-wide loss of function screen using the alphacoronavirus HCoV-229E to better define the interactions between coronaviruses and host factors. We report the identification and validation of an ER-resident host protein, TMEM41B, as an essential host factor for not only HCoV-229E but also genetically distinct coronaviruses including the pandemic betacoronavirus SARS-CoV-2. We show that the protein is required at an early, but post-receptor engagement, stage of the viral lifecycle. Further, mechanistic studies revealed that although the protein was not enriched at replication complexes, it likely contributes to viral replication complex formation via mobilization of cholesterol and other lipids to facilitate host membrane expansion and curvature. Continued study of TMEM41B and the development of approaches to prevent its function may lead to broad spectrum anti-coronavirus therapeutics.

Indexed as

AnimalsAntiviral AgentsCell LineChlorocebus aethiopsCoronavirus 229E, HumanCOVID-19Endoplasmic ReticulumHost Microbial InteractionsHumansMembrane ProteinsSARS-CoV-2Vero CellsVirus ReplicationAntiviral AgentsMembrane ProteinsTMEM41B protein, human

Identifiers

PMID34043740
PMCPMC8189496
OpenAlexW3165843194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.